Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

raloxifene

- PMLiVE

ADA: Boehringer/ Lilly’s empagliflozin shows blood glucose benefits

Phase III results for diabetes candidate also indicate significant weight loss

EU flag

EC fines pharma companies €146m for generic Celexa delay

Lundbeck, Alpharma, Merck KGaA, Generics UK, Arrow and Ranbaxy all hit

- PMLiVE

Pay-for-delay deals ‘sometimes violate antitrust law’

US Supreme Court rules on deals between pharma and generic drug companies

- PMLiVE

Pay-for-delay deals lead to inflated drug prices says study

Based on analysis of delayed market entry of generic Adderall XR in US

- PMLiVE

Safety fears force Lilly to halt BACE inhibitor trial in Alzheimer’s

Patients experience abnormal liver functions in trial

Teva and Sun pay dearly for ‘at-risk’ generic Protonix launch

Will pay $2.15bn in landmark patent infringement lawsuit

- PMLiVE

NICE knocks back Lilly’s Alimta in new setting

Institute not recommending Lilly’s lung cancer drug for new licence extension

EU flag

Nine pharma firms face EU fines over pay-for-delay deals

Lundbeck could be the hardest hit with a maximum penalty of €240m

- PMLiVE

Lilly’s Strattera wins new adult ADHD licence in UK

On course for wider EU approval for adults yet to receive treatment

- PMLiVE

Boehringer/ Lilly launch online diabetes management game

Pharma companies aim to raise awareness of type 2 diabetes complications

- PMLiVE

Another setback for Lilly as lymphoma drug fails

Late-stage candidate enzastaurin shows disappointing phase III results

- PMLiVE

Global biosimilars market to reach $2.45bn in 2013

And EMA plans to revise its guidelines for the area

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links